{
    "thesis_theoretical": [
        {
            "Thesis0": "The influencer believes that the company's strong fundamentals and high growth rate are the key reasons for its impressive returns."
        },
        {
            "Thesis1": "He suggests that the stock is still undervalued, despite its significant growth, and has the potential to become a mid-cap or large-cap stock."
        },
        {
            "Thesis2": "He also highlights the importance of considering factors such as the company's business model, management capabilities, upcoming milestones, and future outlook when conducting a comprehensive fundamental analysis."
        }
    ],
    "thesis_quantitative": [
        {
            "Thesis0": "In the last five years, the stock has given close to 2200% returns."
        },
        {
            "Thesis1": "The company's revenues have been growing at a rate of 26-30%."
        },
        {
            "Thesis2": "The company's earnings per share has been growing at a rate of 44-32%."
        },
        {
            "Thesis3": "The stock's PE is currently at 19, compared to Nifty Pharma PE which is roughly at 31."
        },
        {
            "Thesis4": "The PEG ratio of this stock is currently 0.27."
        }
    ],
    "username": "Rahul Jain"
}